financetom
Business
financetom
/
Business
/
Thermo Fisher Scientific Completes Acquisition of Olink
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Thermo Fisher Scientific Completes Acquisition of Olink
Jul 10, 2024 6:38 AM

09:01 AM EDT, 07/10/2024 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) said Wednesday that it has completed the acquisition of Olink Holding ( OLK ) for about $3.1 billion.

Olink ( OLK ) will become part of Thermo Fisher's Life Sciences Solutions segment.

Thermo Fisher said it accepted about 98.2% of Olink's ( OLK ) outstanding shares and ADSs tendered in its initial offering period, totaling about 84.76 million shares and 37.68 million ADSs.

A subsequent offering period, expiring on July 16, has been initiated during which the remaining shares may be tendered under the same terms, the company said

Price: 521.00, Change: -10.86, Percent Change: -2.04

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Powersports firm RideNow's Q3 revenue beats estimates 
Powersports firm RideNow's Q3 revenue beats estimates 
Nov 4, 2025
Overview * RideNow ( RDNW ) Q3 revenue beats analyst expectations despite a 4.7% yr/yr decline * Adjusted EBITDA for Q3 beats consensus, increasing 80.9% yr/yr * Net loss improved 63.4% to $4.1 mln, driven by powersports segment growth Outlook * RideNow Group ( RDNW ) focuses on powersports segment for future growth * Company aims to leverage 'back to...
Latham Group misses Q3 sales estimates, narrows 2025 net sales guidance
Latham Group misses Q3 sales estimates, narrows 2025 net sales guidance
Nov 4, 2025
Overview * Latham Group ( SWIM ) Q3 net sales grow 7.6% but miss analyst expectations * Adjusted EBITDA for Q3 beats analyst estimates, reflecting strong operational performance * Gross margin expanded by 300 basis points due to acquisitions and operational efficiencies Outlook * Latham narrows 2025 net sales guidance to $540-$550 mln * Adjusted EBITDA guidance for 2025 revised...
Cellular therapy developer Longeveron's Q3 net loss widens
Cellular therapy developer Longeveron's Q3 net loss widens
Nov 4, 2025
Overview * Net loss for Q3 widened to $7.2 mln, driven by increased R&D expenses * Company anticipates pivotal trial results for laromestrocel in 2026, potential BLA submission in 2027 Result Drivers * REVENUE DECLINE - Decrease in revenue driven by reduced demand for Bahamas Registry Trial and contract manufacturing services * R&D EXPENSES - Increase in R&D expenses due...
AI lending platform Upstart Q3 revenue rises
AI lending platform Upstart Q3 revenue rises
Nov 4, 2025
Overview * Upstart Q3 revenue rises 71% YoY, driven by 80% growth in loan originations * GAAP net income for Q3 improves to $31.8 mln from a loss last year * Adjusted EBITDA for Q3 increases to $71.2 mln, reflecting operational efficiency Outlook * Upstart expects Q4 2025 revenue of approximately $288 mln * Company anticipates Q4 2025 GAAP net...
Copyright 2023-2026 - www.financetom.com All Rights Reserved